Do analysts prefer ICCC or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate COCP or CGTX?

Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 280.13%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, COCP or CGTX?

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.76 N/A Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A

Is COCP or CGTX more profitable?

Cognition Therapeutics' return on equity of -50.17% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -207.47% -123.33% Cognition Therapeutics N/A -50.17% -40.22%

Does the media refer more to COCP or CGTX?

In the previous week, Cocrystal Pharma had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 4 mentions for Cocrystal Pharma and 3 mentions for Cognition Therapeutics. Cocrystal Pharma's average media sentiment score of 1.39 beat Cognition Therapeutics' score of 0.80 indicating that Cocrystal Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRCA or COCP?

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 4 articles in the media. Cocrystal Pharma's average media sentiment score of 1.39 beat Verrica Pharmaceuticals' score of 0.78 indicating that Cocrystal Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer COCP or FBIO?

Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 698.12%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Fortress Biotech 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to COCP or FBIO?

In the previous week, Cocrystal Pharma and Cocrystal Pharma both had 4 articles in the media. Cocrystal Pharma's average media sentiment score of 1.39 beat Fortress Biotech's score of 0.44 indicating that Cocrystal Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CING or COCP?

Cingulate presently has a consensus target price of $27.00, indicating a potential upside of 452.15%. Given Cingulate's stronger consensus rating and higher possible upside, research analysts clearly believe Cingulate is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, CING or COCP?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cingulate N/A N/A -$22.45M -$3.59 N/A Cocrystal Pharma N/A N/A -$8.83M -$0.76 N/A

Is CING or COCP more profitable?

Cocrystal Pharma's return on equity of -207.47% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -238.40% -128.67% Cocrystal Pharma N/A -207.47% -123.33%

Cocrystal Pharma (COCP) Competitors

$1.07 0.00 (0.00%)

Closing price 10/9/2026 03:58 PM Eastern

Extended Trading

$1.08 +0.00 (+0.47%)

As of 10/9/2026 04:01 PM Eastern

Compare

COCP vs. ICCC, CGTX, VRCA, FBIO, and CING

Should you buy Cocrystal Pharma stock or one of its competitors? Cocrystal Pharma's main competitors and comparable companies include ImmuCell (ICCC), Cognition Therapeutics (CGTX), Verrica Pharmaceuticals (VRCA), Fortress Biotech (FBIO), and Cingulate (CING). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cocrystal Pharma compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cocrystal Pharma had 3 more articles in the media than ImmuCell. MarketBeat recorded 4 mentions for Cocrystal Pharma and 1 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.82 beat Cocrystal Pharma's score of 1.39 indicating that ImmuCell is being referred to more favorably in the media.

Company	Overall Sentiment
ImmuCell	Very Positive
Cocrystal Pharma	Positive

ImmuCell has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

ImmuCell has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.22	-$1.04M	$0.08	122.50
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A

ImmuCell has a net margin of 2.57% compared to Cocrystal Pharma's net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
Cocrystal Pharma	N/A	-207.47%	-123.33%

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

ImmuCell beats Cocrystal Pharma on 9 of the 13 factors compared between the two stocks.

How does Cocrystal Pharma compare to Cognition Therapeutics?

Cocrystal Pharma (NASDAQ:COCP) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Cocrystal Pharma has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

Cognition Therapeutics' return on equity of -50.17% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Cognition Therapeutics	N/A	-50.17%	-40.22%

Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 280.13%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cocrystal Pharma had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 4 mentions for Cocrystal Pharma and 3 mentions for Cognition Therapeutics. Cocrystal Pharma's average media sentiment score of 1.39 beat Cognition Therapeutics' score of 0.80 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cognition Therapeutics beats Cocrystal Pharma on 8 of the 13 factors compared between the two stocks.

How does Cocrystal Pharma compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Verrica Pharmaceuticals currently has a consensus price target of $12.67, suggesting a potential upside of 208.19%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Verrica Pharmaceuticals is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Verrica Pharmaceuticals has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Cocrystal Pharma has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Cocrystal Pharma's return on equity of -207.47% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Cocrystal Pharma	N/A	-207.47%	-123.33%

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 4 articles in the media. Cocrystal Pharma's average media sentiment score of 1.39 beat Verrica Pharmaceuticals' score of 0.78 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cocrystal Pharma has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	1.98	-$17.89M	-$1.67	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A

Summary

Verrica Pharmaceuticals beats Cocrystal Pharma on 8 of the 14 factors compared between the two stocks.

How does Cocrystal Pharma compare to Fortress Biotech?

Cocrystal Pharma (NASDAQ:COCP) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Fortress Biotech has a net margin of 163.32% compared to Cocrystal Pharma's net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Fortress Biotech	163.32%	83.47%	42.98%

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cocrystal Pharma and Cocrystal Pharma both had 4 articles in the media. Cocrystal Pharma's average media sentiment score of 1.39 beat Fortress Biotech's score of 0.44 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cocrystal Pharma has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 698.12%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fortress Biotech	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Fortress Biotech has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A
Fortress Biotech	$63.26M	1.12	$6.82M	$2.64	0.81

Summary

Fortress Biotech beats Cocrystal Pharma on 11 of the 14 factors compared between the two stocks.

How does Cocrystal Pharma compare to Cingulate?

Cingulate (NASDAQ:CING) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Cocrystal Pharma's return on equity of -207.47% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-238.40%	-128.67%
Cocrystal Pharma	N/A	-207.47%	-123.33%

In the previous week, Cocrystal Pharma had 3 more articles in the media than Cingulate. MarketBeat recorded 4 mentions for Cocrystal Pharma and 1 mentions for Cingulate. Cingulate's average media sentiment score of 1.82 beat Cocrystal Pharma's score of 1.39 indicating that Cingulate is being referred to more favorably in the media.

Company	Overall Sentiment
Cingulate	Very Positive
Cocrystal Pharma	Positive

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 5.3% of Cingulate shares are owned by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cingulate presently has a consensus target price of $27.00, indicating a potential upside of 452.15%. Given Cingulate's stronger consensus rating and higher possible upside, research analysts clearly believe Cingulate is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cingulate has a beta of -0.88, meaning that its share price is 188% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Summary

Cocrystal Pharma beats Cingulate on 7 of the 13 factors compared between the two stocks.

Get Cocrystal Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COCP vs. The Competition

Export

Metric	Cocrystal Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$20.61M	$12.39B	$7.25B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	22.58%
P/E Ratio	-1.41	800.13	275.59	26.13
Price / Sales	N/A	754.43	586.27	86.30
Price / Cash	N/A	15.28	27.30	36.12
Price / Book	2.33	9.15	10.82	6.16
Net Income	-$8.83M	$2.84B	$3.50B	$381.12M
7 Day Performance	-3.60%	-0.88%	-1.19%	-1.43%
1 Month Performance	-13.71%	-3.66%	-4.00%	-3.36%
1 Year Performance	-6.96%	-3.95%	7.13%	1.49%

Cocrystal Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COCP Cocrystal Pharma	2.2846 of 5 stars	$1.07 flat	N/A	-7.0%	$20.61M	N/A	N/A	10	Positive News Analyst Forecast Short Interest Decrease Analyst Revision
ICCC ImmuCell	0.9053 of 5 stars	$9.94 +0.6%	N/A	+44.1%	$89.73M	$27.64M	124.27	73
CGTX Cognition Therapeutics	2.197 of 5 stars	$0.95 +1.7%	$3.33 +249.3%	-52.1%	$89.24M	N/A	N/A	14	News Coverage
VRCA Verrica Pharmaceuticals	3.8762 of 5 stars	$4.46 -3.0%	$12.67 +184.0%	-0.7%	$79.02M	$35.58M	N/A	76	Gap Up
FBIO Fortress Biotech	2.6497 of 5 stars	$2.20 +1.4%	$17.00 +672.7%	-21.4%	$72.37M	$63.26M	0.83	78	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COCP) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cocrystal Pharma (COCP) Competitors

COCP vs. ICCC, CGTX, VRCA, FBIO, and CING

How does Cocrystal Pharma compare to ImmuCell?

Summary

How does Cocrystal Pharma compare to Cognition Therapeutics?

Summary

How does Cocrystal Pharma compare to Verrica Pharmaceuticals?

Summary

How does Cocrystal Pharma compare to Fortress Biotech?

Summary

How does Cocrystal Pharma compare to Cingulate?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cocrystal Pharma (COCP) Competitors

COCP vs. ICCC, CGTX, VRCA, FBIO, and CING

How does Cocrystal Pharma compare to ImmuCell?

Do analysts prefer ICCC or COCP?

Does the media favor ICCC or COCP?

Which has more volatility and risk, ICCC or COCP?

Which has stronger valuation & earnings, ICCC or COCP?

Is ICCC or COCP more profitable?

Do insiders and institutionals hold more shares of ICCC or COCP?

Summary

How does Cocrystal Pharma compare to Cognition Therapeutics?

Which has more volatility and risk, COCP or CGTX?

Do insiders & institutionals believe in COCP or CGTX?

Which has stronger earnings & valuation, COCP or CGTX?

Is COCP or CGTX more profitable?

Do analysts rate COCP or CGTX?

Does the media refer more to COCP or CGTX?

Summary

How does Cocrystal Pharma compare to Verrica Pharmaceuticals?

Do analysts prefer VRCA or COCP?

Which has more risk & volatility, VRCA or COCP?

Is VRCA or COCP more profitable?

Does the media refer more to VRCA or COCP?

Do insiders & institutionals hold more shares of VRCA or COCP?

Which has higher earnings and valuation, VRCA or COCP?

Summary

How does Cocrystal Pharma compare to Fortress Biotech?

Is COCP or FBIO more profitable?

Do insiders and institutionals believe in COCP or FBIO?

Does the media refer more to COCP or FBIO?

Which has more risk and volatility, COCP or FBIO?

Do analysts prefer COCP or FBIO?

Which has stronger earnings and valuation, COCP or FBIO?

Summary

How does Cocrystal Pharma compare to Cingulate?

Is CING or COCP more profitable?

Does the media favor CING or COCP?

Which has stronger valuation & earnings, CING or COCP?

Do institutionals and insiders have more ownership in CING or COCP?

Do analysts prefer CING or COCP?

Which has more volatility & risk, CING or COCP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools